Orchestra BioMed (NASDAQ:OBIO) Director Buys $82,600.00 in Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Eric Fain acquired 20,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were bought at an average cost of $4.13 per share, with a total value of $82,600.00. Following the acquisition, the director directly owned 91,709 shares in the company, valued at approximately $378,758.17. The trade was a 27.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Orchestra BioMed Price Performance

OBIO opened at $3.72 on Monday. The firm has a 50-day simple moving average of $4.29 and a two-hundred day simple moving average of $4.27. Orchestra BioMed Holdings, Inc. has a 52 week low of $2.20 and a 52 week high of $5.42. The company has a market capitalization of $222.76 million, a PE ratio of -3.84 and a beta of 0.52. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.92 million. Analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OBIO has been the topic of several recent research reports. Barclays upped their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings cut shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday, March 12th. Wall Street Zen cut shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Orchestra BioMed in a research report on Thursday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Institutional Trading of Orchestra BioMed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after acquiring an additional 324,558 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in Orchestra BioMed in the 3rd quarter worth about $3,386,000. Pathstone Holdings LLC bought a new position in Orchestra BioMed in the 3rd quarter worth about $2,495,000. Geode Capital Management LLC grew its stake in Orchestra BioMed by 22.4% in the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock worth $1,965,000 after acquiring an additional 86,564 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Orchestra BioMed by 46.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock worth $1,095,000 after acquiring an additional 83,349 shares in the last quarter. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.